NIKKEI 225
28,275.79 +151.51 (+0.54%) HANG SENG
24,227.41 -155.91 (-0.64%) CRUDE OIL
84.36 +0.54 (+0.64%) GOLD FUTURES
1,816.10 -0.40 (-0.02%) DOW
35,911.81 -201.79 (-0.56%) BTC-GBP
31,407.34 -234.56 (-0.74%)
Silence Therapeutics plc (SLNCF)
- Globe Newswire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference 5 January 2022 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a fireside chat during the H.C. Wainwright BioConnect Virtual Conferen
- Globe Newswire
New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases
New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases Data presented at 2021 ASH annual meeting showed durable reductions in serum iron and transferrin saturation, strong safety profile and long duration of action Data support ongoing studies in patients with thalassemia and myelodysplastic syndrome and a new planned study in polycythemia vera 12 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a lead
- Globe Newswire
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Deep Track Capital, a U.S. investment firm focused exclusively on the life sciences industry, purchased approximately $22 million of American Depository Shares (ADSs) in Silence from existing shareholder
